Open label dose escalation ph[ase]. I trial of MK-0646 [etoricoxib] given as a one to two hour every other week infusion in patients with relapsed or refractory locally advanced or metastatic cancers
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2007
At a glance
- Drugs Etoricoxib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 18 Jun 2007 New trial record.